MorphoSys AG buy Haans
Summary
This prediction ended on 19.05.17 with a price of €60.61. The prediction had a final performance of 21.25%. Haans has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| MorphoSys AG | -2.066% | -2.066% | 251.523% | -15.628% |
| iShares Core DAX® | 0.000% | -2.064% | 13.111% | 16.685% |
| iShares Nasdaq 100 | 0.626% | -2.884% | 37.744% | 43.441% |
| iShares Nikkei 225® | 1.568% | -5.892% | 19.592% | 4.617% |
| iShares S&P 500 | 0.334% | -2.281% | 27.745% | 41.046% |
Comments by Haans for this prediction
In the thread Morphosys AG diskutieren
Morphosys.....
Der kurz-, mittel und langfristige Trend ist aufwärts gerichtet, und der Trend ist dein Freud. Die Aktie zeigt zur Zeit eine deutliche Stärke, und denn noch, unter 44 Euro sollte sie nicht mehr fallen. Evtl. gestaffelter Einstieg.